Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a gap, strategically or scientifically, we're looking outside to see how we can fill the gaps." (Source: Bloomberg)
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.